COHR notches record results
Independent service organization COHR continues to reap the rewards of its aggressive business plan. The Chatsworth, CA-based firm announced record fourth-quarter and fiscal 1997 results.COHR reported revenues of $25.4 million for its fourth quarter
Independent service organization COHR continues to reap the rewards of its aggressive business plan. The Chatsworth, CA-based firm announced record fourth-quarter and fiscal 1997 results.
COHR reported revenues of $25.4 million for its fourth quarter (end-March), a 36% increase over the $18.7 million posted in the same period in 1996. Net income was $1.5 million, compared with $700,000 for the fourth quarter of 1996.
For its fiscal year (end-March), COHR reported revenues of $90.5 million, a 37% boost over the $66.3 million reported for the same period in 1996. At the time, the $66.3 million represented a fiscal-year record for COHR. Net income for fiscal year 1997 was $4.9 million, compared with $2.1 million reported in fiscal 1996.
The company credited its recent acquisitions, as well as a 42% growth in its equipment service business, as key drivers in the strong fiscal 1997 performance. COHR acquired nine companies in the last year and has purchased 21 equipment service businesses nationwide since July 1993. Several other companies are in COHR's acquisition pipeline, according to COHR.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
